Treatment of lupus skin involvement with quinacrine and hydroxychloroquine
To evaluate the efficacy of hydroxychloroquine (HCQ) and quinacrine (Qn) association, at two different dosages, in treatment of lupus skin lesions not responding to HCQ alone. Thirty-four patients, affected by cutaneous and systemic lupus erythematosus, were retrospectively analysed. They were treat...
Gespeichert in:
| Veröffentlicht in: | Lupus 2009-07, Vol.18 (8), p.735-739 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 739 |
|---|---|
| container_issue | 8 |
| container_start_page | 735 |
| container_title | Lupus |
| container_volume | 18 |
| creator | Cavazzana, I Sala, R Bazzani, C Ceribelli, A Zane, C Cattaneo, R Tincani, A Calzavara-Pinton, PG Franceschini, F |
| description | To evaluate the efficacy of hydroxychloroquine (HCQ) and quinacrine (Qn) association, at two different dosages, in treatment of lupus skin lesions not responding to HCQ alone. Thirty-four patients, affected by cutaneous and systemic lupus erythematosus, were retrospectively analysed. They were treated by HCQ (5 mg/Kg/qd) and Qn with two regimens: 100 mg/qd (29 cases) and 50 mg/qd (5 cases). Discoid lupus erythematosus (19 cases), acute malar rash (6 cases), chilblain lupus (4 cases) showed a significant improvement with combination therapy (P = 0.009, P = 0.019, and P = 0.04, respectively). Ten patients with subacute cutaneous lupus showed a partial response, whereas lupus profundus didn’t improve. The same overall response rate was recorded comparing two Qn regimens, but subjects taking 100 mg/qd improved more rapidly than the others (P = 0.001). Ten patients developed side effects, mainly represented by skin yellowish discolouration. Depression and severe headache with nausea, which were globally recorded in two cases, led to drug withdrawal. One additional case of hepatitis was recorded in a patient with preexisting Hepatitis C virus (HCV) infection. Combination of HCQ and Qn is rapidly effective at 100 mg/qd and well tolerated in the treatment of lupus skin lesions unresponsive to HCQ alone. |
| doi_str_mv | 10.1177/0961203308101714 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67336085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203308101714</sage_id><sourcerecordid>20125889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-74983c48b19b3252f164733c3bd65e230a1a5f088598af5d4b13addbb9f3c3613</originalsourceid><addsrcrecordid>eNqFkctLw0AQxhdRbK3ePUnw4C06s5t9HUV8UvBSz2GTbGxqHnU3qfa_N7GFQkE8Dcz3m-9jZgg5R7hGlPIGtEAKjIFCQInRARljJGXY9-khGQ9yOOgjcuL9AgAYanFMRqg5UCphTF5mzpq2snUbNHlQdsvOB_6jqIOiXjXlyv4qX0U7Dz67ojapK2obmDoL5uvMNd_rdF42rhk0e0qOclN6e7atE_L2cD-7ewqnr4_Pd7fTMGWataGMtGJppBLUCaOc5igiyVjKkkxwSxkYNDwHpbhWJudZlCAzWZYkOu8hgWxCrja-yyHY-jauCp_asjS1bTofi95NgOL_ghSQcqV0D17ugYumc3W_REwpFYCKD7GwgVLXeO9sHi9dURm3jhHi4Rvx_jf6kYutb5dUNtsNbM_fA-EG8Obd7kL_NPwBgtOQuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222601851</pqid></control><display><type>article</type><title>Treatment of lupus skin involvement with quinacrine and hydroxychloroquine</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Cavazzana, I ; Sala, R ; Bazzani, C ; Ceribelli, A ; Zane, C ; Cattaneo, R ; Tincani, A ; Calzavara-Pinton, PG ; Franceschini, F</creator><creatorcontrib>Cavazzana, I ; Sala, R ; Bazzani, C ; Ceribelli, A ; Zane, C ; Cattaneo, R ; Tincani, A ; Calzavara-Pinton, PG ; Franceschini, F</creatorcontrib><description>To evaluate the efficacy of hydroxychloroquine (HCQ) and quinacrine (Qn) association, at two different dosages, in treatment of lupus skin lesions not responding to HCQ alone. Thirty-four patients, affected by cutaneous and systemic lupus erythematosus, were retrospectively analysed. They were treated by HCQ (5 mg/Kg/qd) and Qn with two regimens: 100 mg/qd (29 cases) and 50 mg/qd (5 cases). Discoid lupus erythematosus (19 cases), acute malar rash (6 cases), chilblain lupus (4 cases) showed a significant improvement with combination therapy (P = 0.009, P = 0.019, and P = 0.04, respectively). Ten patients with subacute cutaneous lupus showed a partial response, whereas lupus profundus didn’t improve. The same overall response rate was recorded comparing two Qn regimens, but subjects taking 100 mg/qd improved more rapidly than the others (P = 0.001). Ten patients developed side effects, mainly represented by skin yellowish discolouration. Depression and severe headache with nausea, which were globally recorded in two cases, led to drug withdrawal. One additional case of hepatitis was recorded in a patient with preexisting Hepatitis C virus (HCV) infection. Combination of HCQ and Qn is rapidly effective at 100 mg/qd and well tolerated in the treatment of lupus skin lesions unresponsive to HCQ alone.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203308101714</identifier><identifier>PMID: 19502270</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Antibodies ; Antimalarials - therapeutic use ; Antirheumatic Agents - therapeutic use ; Connective tissue ; Disease ; Drug dosages ; Female ; Hepatitis ; Hepatitis C virus ; Humans ; Hydroxychloroquine - therapeutic use ; Immunosuppressive agents ; Lupus ; Lupus Erythematosus, Cutaneous - drug therapy ; Lupus Erythematosus, Cutaneous - pathology ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - pathology ; Male ; Middle Aged ; Patients ; Quinacrine - therapeutic use ; Retrospective Studies ; Rheumatology ; Skin - pathology ; Steroids ; Treatment Outcome</subject><ispartof>Lupus, 2009-07, Vol.18 (8), p.735-739</ispartof><rights>SAGE Publications © Jul 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-74983c48b19b3252f164733c3bd65e230a1a5f088598af5d4b13addbb9f3c3613</citedby><cites>FETCH-LOGICAL-c393t-74983c48b19b3252f164733c3bd65e230a1a5f088598af5d4b13addbb9f3c3613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203308101714$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203308101714$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,778,782,21802,27907,27908,43604,43605</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19502270$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cavazzana, I</creatorcontrib><creatorcontrib>Sala, R</creatorcontrib><creatorcontrib>Bazzani, C</creatorcontrib><creatorcontrib>Ceribelli, A</creatorcontrib><creatorcontrib>Zane, C</creatorcontrib><creatorcontrib>Cattaneo, R</creatorcontrib><creatorcontrib>Tincani, A</creatorcontrib><creatorcontrib>Calzavara-Pinton, PG</creatorcontrib><creatorcontrib>Franceschini, F</creatorcontrib><title>Treatment of lupus skin involvement with quinacrine and hydroxychloroquine</title><title>Lupus</title><addtitle>Lupus</addtitle><description>To evaluate the efficacy of hydroxychloroquine (HCQ) and quinacrine (Qn) association, at two different dosages, in treatment of lupus skin lesions not responding to HCQ alone. Thirty-four patients, affected by cutaneous and systemic lupus erythematosus, were retrospectively analysed. They were treated by HCQ (5 mg/Kg/qd) and Qn with two regimens: 100 mg/qd (29 cases) and 50 mg/qd (5 cases). Discoid lupus erythematosus (19 cases), acute malar rash (6 cases), chilblain lupus (4 cases) showed a significant improvement with combination therapy (P = 0.009, P = 0.019, and P = 0.04, respectively). Ten patients with subacute cutaneous lupus showed a partial response, whereas lupus profundus didn’t improve. The same overall response rate was recorded comparing two Qn regimens, but subjects taking 100 mg/qd improved more rapidly than the others (P = 0.001). Ten patients developed side effects, mainly represented by skin yellowish discolouration. Depression and severe headache with nausea, which were globally recorded in two cases, led to drug withdrawal. One additional case of hepatitis was recorded in a patient with preexisting Hepatitis C virus (HCV) infection. Combination of HCQ and Qn is rapidly effective at 100 mg/qd and well tolerated in the treatment of lupus skin lesions unresponsive to HCQ alone.</description><subject>Adult</subject><subject>Antibodies</subject><subject>Antimalarials - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Connective tissue</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hepatitis C virus</subject><subject>Humans</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Immunosuppressive agents</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Cutaneous - drug therapy</subject><subject>Lupus Erythematosus, Cutaneous - pathology</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Quinacrine - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Skin - pathology</subject><subject>Steroids</subject><subject>Treatment Outcome</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkctLw0AQxhdRbK3ePUnw4C06s5t9HUV8UvBSz2GTbGxqHnU3qfa_N7GFQkE8Dcz3m-9jZgg5R7hGlPIGtEAKjIFCQInRARljJGXY9-khGQ9yOOgjcuL9AgAYanFMRqg5UCphTF5mzpq2snUbNHlQdsvOB_6jqIOiXjXlyv4qX0U7Dz67ojapK2obmDoL5uvMNd_rdF42rhk0e0qOclN6e7atE_L2cD-7ewqnr4_Pd7fTMGWataGMtGJppBLUCaOc5igiyVjKkkxwSxkYNDwHpbhWJudZlCAzWZYkOu8hgWxCrja-yyHY-jauCp_asjS1bTofi95NgOL_ghSQcqV0D17ugYumc3W_REwpFYCKD7GwgVLXeO9sHi9dURm3jhHi4Rvx_jf6kYutb5dUNtsNbM_fA-EG8Obd7kL_NPwBgtOQuw</recordid><startdate>20090701</startdate><enddate>20090701</enddate><creator>Cavazzana, I</creator><creator>Sala, R</creator><creator>Bazzani, C</creator><creator>Ceribelli, A</creator><creator>Zane, C</creator><creator>Cattaneo, R</creator><creator>Tincani, A</creator><creator>Calzavara-Pinton, PG</creator><creator>Franceschini, F</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>7X8</scope></search><sort><creationdate>20090701</creationdate><title>Treatment of lupus skin involvement with quinacrine and hydroxychloroquine</title><author>Cavazzana, I ; Sala, R ; Bazzani, C ; Ceribelli, A ; Zane, C ; Cattaneo, R ; Tincani, A ; Calzavara-Pinton, PG ; Franceschini, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-74983c48b19b3252f164733c3bd65e230a1a5f088598af5d4b13addbb9f3c3613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Antibodies</topic><topic>Antimalarials - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Connective tissue</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hepatitis C virus</topic><topic>Humans</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Immunosuppressive agents</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Cutaneous - drug therapy</topic><topic>Lupus Erythematosus, Cutaneous - pathology</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Quinacrine - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Skin - pathology</topic><topic>Steroids</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cavazzana, I</creatorcontrib><creatorcontrib>Sala, R</creatorcontrib><creatorcontrib>Bazzani, C</creatorcontrib><creatorcontrib>Ceribelli, A</creatorcontrib><creatorcontrib>Zane, C</creatorcontrib><creatorcontrib>Cattaneo, R</creatorcontrib><creatorcontrib>Tincani, A</creatorcontrib><creatorcontrib>Calzavara-Pinton, PG</creatorcontrib><creatorcontrib>Franceschini, F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cavazzana, I</au><au>Sala, R</au><au>Bazzani, C</au><au>Ceribelli, A</au><au>Zane, C</au><au>Cattaneo, R</au><au>Tincani, A</au><au>Calzavara-Pinton, PG</au><au>Franceschini, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of lupus skin involvement with quinacrine and hydroxychloroquine</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2009-07-01</date><risdate>2009</risdate><volume>18</volume><issue>8</issue><spage>735</spage><epage>739</epage><pages>735-739</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>To evaluate the efficacy of hydroxychloroquine (HCQ) and quinacrine (Qn) association, at two different dosages, in treatment of lupus skin lesions not responding to HCQ alone. Thirty-four patients, affected by cutaneous and systemic lupus erythematosus, were retrospectively analysed. They were treated by HCQ (5 mg/Kg/qd) and Qn with two regimens: 100 mg/qd (29 cases) and 50 mg/qd (5 cases). Discoid lupus erythematosus (19 cases), acute malar rash (6 cases), chilblain lupus (4 cases) showed a significant improvement with combination therapy (P = 0.009, P = 0.019, and P = 0.04, respectively). Ten patients with subacute cutaneous lupus showed a partial response, whereas lupus profundus didn’t improve. The same overall response rate was recorded comparing two Qn regimens, but subjects taking 100 mg/qd improved more rapidly than the others (P = 0.001). Ten patients developed side effects, mainly represented by skin yellowish discolouration. Depression and severe headache with nausea, which were globally recorded in two cases, led to drug withdrawal. One additional case of hepatitis was recorded in a patient with preexisting Hepatitis C virus (HCV) infection. Combination of HCQ and Qn is rapidly effective at 100 mg/qd and well tolerated in the treatment of lupus skin lesions unresponsive to HCQ alone.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>19502270</pmid><doi>10.1177/0961203308101714</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2009-07, Vol.18 (8), p.735-739 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67336085 |
| source | MEDLINE; SAGE Complete |
| subjects | Adult Antibodies Antimalarials - therapeutic use Antirheumatic Agents - therapeutic use Connective tissue Disease Drug dosages Female Hepatitis Hepatitis C virus Humans Hydroxychloroquine - therapeutic use Immunosuppressive agents Lupus Lupus Erythematosus, Cutaneous - drug therapy Lupus Erythematosus, Cutaneous - pathology Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - pathology Male Middle Aged Patients Quinacrine - therapeutic use Retrospective Studies Rheumatology Skin - pathology Steroids Treatment Outcome |
| title | Treatment of lupus skin involvement with quinacrine and hydroxychloroquine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T01%3A53%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20lupus%20skin%20involvement%20with%20quinacrine%20and%20hydroxychloroquine&rft.jtitle=Lupus&rft.au=Cavazzana,%20I&rft.date=2009-07-01&rft.volume=18&rft.issue=8&rft.spage=735&rft.epage=739&rft.pages=735-739&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203308101714&rft_dat=%3Cproquest_cross%3E20125889%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222601851&rft_id=info:pmid/19502270&rft_sage_id=10.1177_0961203308101714&rfr_iscdi=true |